BACKGROUND: The number of elderly women with breast cancer is increasing and will become a major health concern. However, little is known about the optimal treatment for this age group. The aim of this study was to describe time trends for the overall Dutch breast cancer cohort with an emphasis on differences between young and elderly patients. METHODS: All adult female patients diagnosed in 1995-2005 were selected from the Netherlands Cancer Registry. Relative excess risks for death (adjusted for stage, histology, treatment, and grade) were estimated using a multivariate generalized linear model with a Poisson distribution, based on collapsed relative survival data, using exact survival times. RESULTS: Overall, 127,805 patients were included. Treatment of patients aged ≥75 years changed significantly over time: they received less surgery, more adjuvant hormonal treatment and chemotherapy, and more hormonal treatment without surgery. In contrast to younger patients, the relative survival did not improve significantly over time for elderly patients. With increasing age, the observed-expected death ratio decreased to almost 1.0. CONCLUSION: Survival for elderly patients with breast cancer did not improve significantly. Observed-expected death ratios in the elderly are close to 1, indicating that excess mortality is low. Elderly patients with breast cancer have a higher risk for overtreatment and undertreatment, with a delicate therapeutic balance between breast cancer survival gain and potential toxicities. To improve breast cancer survival in the elderly, a critical reappraisal is needed of costs and benefits of hormonal as well as other treatments, and better selection of patients who can benefit from available therapies is warranted.
BACKGROUND: The number of elderly women with breast cancer is increasing and will become a major health concern. However, little is known about the optimal treatment for this age group. The aim of this study was to describe time trends for the overall Dutch breast cancer cohort with an emphasis on differences between young and elderly patients. METHODS: All adult female patients diagnosed in 1995-2005 were selected from the Netherlands Cancer Registry. Relative excess risks for death (adjusted for stage, histology, treatment, and grade) were estimated using a multivariate generalized linear model with a Poisson distribution, based on collapsed relative survival data, using exact survival times. RESULTS: Overall, 127,805 patients were included. Treatment of patients aged ≥75 years changed significantly over time: they received less surgery, more adjuvant hormonal treatment and chemotherapy, and more hormonal treatment without surgery. In contrast to younger patients, the relative survival did not improve significantly over time for elderly patients. With increasing age, the observed-expected death ratio decreased to almost 1.0. CONCLUSION: Survival for elderly patients with breast cancer did not improve significantly. Observed-expected death ratios in the elderly are close to 1, indicating that excess mortality is low. Elderly patients with breast cancer have a higher risk for overtreatment and undertreatment, with a delicate therapeutic balance between breast cancer survival gain and potential toxicities. To improve breast cancer survival in the elderly, a critical reappraisal is needed of costs and benefits of hormonal as well as other treatments, and better selection of patients who can benefit from available therapies is warranted.
Authors: W J Louwman; M L G Janssen-Heijnen; S Houterman; A C Voogd; M J C van der Sangen; G A P Nieuwenhuijzen; J W W Coebergh Journal: Eur J Cancer Date: 2005-03 Impact factor: 9.162
Authors: W J Louwman; J C M Vulto; R H A Verhoeven; G A P Nieuwenhuijzen; J W W Coebergh; A C Voogd Journal: Eur J Cancer Date: 2007-09-17 Impact factor: 9.162
Authors: L Bergman; G Dekker; E H van Kerkhoff; H L Peterse; J A van Dongen; F E van Leeuwen Journal: Breast Cancer Res Treat Date: 1991-08 Impact factor: 4.872
Authors: Esther M de Kruijf; Esther Bastiaannet; Francesca Rubertá; Anton J M de Craen; Peter J K Kuppen; Vincent T H B M Smit; Cornelis J H van de Velde; Gerrit Jan Liefers Journal: Mol Oncol Date: 2014-04-08 Impact factor: 6.603
Authors: Gloria J Morris; Kristine Swartz; Andrew E Chapman; Stuart M Lichtman; Jason S Levitz; Farhad Ravandi; Kathryn R Chan Journal: Semin Oncol Date: 2012-10 Impact factor: 4.929
Authors: A-M Grumpelt; A Ignatov; S N Tchaikovski; E Burger; S-D Costa; H Eggemann Journal: J Cancer Res Clin Oncol Date: 2016-01-25 Impact factor: 4.553
Authors: Clark DuMontier; Kah Poh Loh; Paul A Bain; Rebecca A Silliman; Tammy Hshieh; Gregory A Abel; Benjamin Djulbegovic; Jane A Driver; William Dale Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 50.717
Authors: N A de Glas; C C Engels; E Bastiaannet; W van de Water; S Siesling; A J M de Craen; C J H van de Velde; G J Liefers; J W S Merkus Journal: Breast Cancer Res Treat Date: 2015-02-13 Impact factor: 4.872
Authors: Janine K Cataldo; Steven Paul; Bruce Cooper; Helen Skerman; Kimberly Alexander; Bradley Aouizerat; Virginia Blackman; John Merriman; Laura Dunn; Christine Ritchie; Patsy Yates; Christine Miaskowski Journal: BMC Cancer Date: 2013-01-03 Impact factor: 4.430